Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2019-09-25
2021-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain
NCT00226421
The Effects of Patient Features on Opioid Induced End-Tidal CO2
NCT01371903
Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
NCT00225797
Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
NCT01717027
OXY-2: The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models
NCT00271973
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Group
Study Group - 36 patients with chronic Low-Back Pain with opioids pharmacotherapy
biochemical measurements
TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
Control Group
Control Group - 14 patients, healthy volunteers.
biochemical measurements
TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biochemical measurements
TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Bialystok
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Urszula Kosciuczuk
Role: PRINCIPAL_INVESTIGATOR
Medical University in Bialystok
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urszula Kosciuczuk
Bialystok, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R-I-002/307/2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.